SCHEMBL13675536

SCHEMBL13675536

CCOC(=O)C1CNc2cc(N)ccc2O1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.46
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
KMT2A Q03164 4/20 0.45
HPGD P15428 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 1/20 0.42
TNF P01375 2/20 0.41
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 2/20 0.38
LMNA P02545 1/20 0.36
MAOA P21397 1/20 0.36
SHMT2 P34897 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYSLTR1 Q9Y271 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11561609 0.99 HSD17B10 (0.46) HSD17B10CYP4F2CYP4A11KMT2AHPGD
SCHEMBL7817820 0.87 HSD17B10 (0.60) HSD17B10CYP4F2CYP4A11KMT2AHPGD
Hydrochloric Acid SCHEMBL11562060 0.86 HSD17B10 (0.59) HSD17B10CYP4F2CYP4A11KMT2AHPGD
SCHEMBL13285093 0.86 KMT2A (0.47) HSD17B10KMT2AHPGDCYP1A2CYP3A4
SCHEMBL7819909 0.85 HSD17B10 (0.46) HSD17B10CYP4F2CYP4A11KMT2AHPGD
SCHEMBL750101 0.85 HSD17B10 (0.46) HSD17B10CYP4F2CYP4A11KMT2AHPGD
SCHEMBL3353094 0.85 POLB (0.55) HSD17B10CYP4F2CYP4A11KMT2AHPGD
SCHEMBL29527171 0.85 POLB (0.55) HSD17B10CYP4F2CYP4A11KMT2AHPGD
SCHEMBL23420329 0.84 HSD17B10 (0.46) HSD17B10CYP4F2CYP4A11KMT2AHPGD
SCHEMBL7818765 0.84 ALDH1A1 (0.48) HSD17B10CYP4F2CYP4A11KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
EP-1780196-A2 Pyridine derivatives for use as vanilloid receptor ligands Amgen, Inc (US) 2007-05-02 EP disclosed
EP-1764358-A2 Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain Amgen, Inc (US) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 HSD17B10 3096/4885CYP4F2 3471/4885CYP4A11 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.